News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Humberto C. Antunes Named Galderma Laboratories Worldwide CEO

10/19/2005 5:10:26 PM

FT. WORTH, Texas, March 15 /PRNewswire/ -- Humberto C. Antunes, president of Galderma Laboratories, L.P., the nation's leading pharmaceutical company devoted entirely to the development and marketing of pharmaceutical and OTC dermatology products, has been named Chief Executive Officer of Galderma worldwide, based in Lausanne, Switzerland. Galderma's corporate services headquarters are based in Paris, France. Mr. Antunes will relocate to Paris in May 2004 to succeed Xavier Yon, the current CEO of Galderma, who is retiring. In the United States, Mr. Antunes will be succeeded by Albert Draaijer.

Galderma is one of the world's leading specialty pharmaceutical companies, focused exclusively on research, development and marketing of dermatology products. The company deploys a worldwide network of thirty-three fully owned subsidiaries with products marketed in more than seventy countries. Galderma Laboratories, L.P. is the United States subsidiary of Galderma worldwide.

Mr. Antunes' background makes him uniquely qualified to head Galderma's worldwide operations. He has over twenty years experience in the pharmaceutical industry. Prior to his appointment in 2000 as president of Galderma in the United States, he managed one of the largest and fastest-growing dermatology markets outside the U.S.A as president of Galderma Brazil and head of nine subsidiaries in Latin America.

Albert Draaijer will become the new president of Galderma Laboratories, L.P., effective, June 1, 2004. He will replace Mr. Antunes as head of North American operations, which includes the United States and Canada. Mr. Draaijer's recent responsibility has been as head of Galderma's European operations. He has a 21-year background in the pharmaceutical industry, including: General Manager, Sanofi-Synthelabo, Scandinavia; General Manager, Director of Marketing, and National Sales Manager, Lorex Synthelabo, Holland.

In his new position, Mr. Draaijer will oversee Galderma's current portfolio of dermatological products, including: Differin(R) Gel, MetroGel(R), Rozex(TM) Emulsion, Tri-Luma(R) Cream, Clobex(TM) Lotion and Clobex(TM) Shampoo, which recently received FDA approval, Cetaphil(R) Cleansers and Moisturizers, Solage(R) Solution, Capex(R) Shampoo and DesOwen(R) Lotion.

Galderma Laboratories, L.P.

CONTACT: Suzanne Lane of Lane & Coady P.R., of +1-212-757-6880,, for Galderma Laboratories, L.P.

Read at

comments powered by Disqus